Britain and America have agreed to a significant bilateral deal that will maintain zero import taxes on British drug shipments being sold in the US market.
The Terms of the Pact
Under the terms of the agreement, the UK has committed to increase expenditure on drugs through the public health system. This commitment ensures that tariffs on these vital products will remain at nothing for a timeframe of the next three years.
This development is in response to earlier warnings to dramatically increase import taxes on branded pharmaceutical products, with figures floated reaching one hundred percent.
"This deal with the UK bolsters the worldwide climate for new treatments and establishes long-overdue equity to U.S.–U.K. medicine commerce," a statement noted.
Commercial Importance
Drugs represent one of the Britain's most significant goods shipped to the US, which is easily the largest market for leading UK drugmakers.
Statistics show that in the one-year period to the end of the third quarter, the UK shipped pharmaceutical products valued at £11.1bn to the US. This amount made up nearly one-fifth of total UK exports in that period.
"This deal protects work, stimulates investment and paves the way for the UK to become a international leader for medical research," a government official commented.
Detailed UK Commitments
The pact involves several key changes from the United Kingdom:
- Price Threshold Increase: The UK will increase the cost ceiling at which it judges new treatments to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a goal to increase total NHS spending on drugs from 0.3 percent of the national economy to 0.6% over the next decade.
- Rebate Cap: The sum manufacturers must pay back to the NHS to stay within budget will be limited at 15%. Last year, rebates were more than 20%.
Industry Background
The pact comes amid a ongoing row between the pharmaceutical industry and the UK government over drug pricing and NHS adoption.
This friction were exacerbated by assertions that US patients were paying several times more for the same drugs than consumers in the Britain and the EU.
Recently, several large pharmaceutical investments in the UK have been delayed or abandoned, while substantial funding commitments have been pledged toward US facilities.
The Science Minister acknowledged that the NHS must increase expenditure on treatments, noting that its spending on drugs had decreased as a percentage of its resources over the last ten years.
